An international team of scientists, led by researchers from Imperial College London and the University of Exeter, have found that levels of resistance to fungal infection treatments are rising, BBC News reported on Friday.
The findings, which have been published in Science, reveal a huge global increase in resistance to antifungal drugs over the last 30-40 years and that fungal infections have some of the highest mortality rates of infectious diseases.
The researchers are calling for new treatments, saying they are urgently needed.
Due to their weakened immune systems, transplant patients, those in intensive care, and cancer patients are most at risk.
The researchers also discovered a rise of new multidrug-resistant fungi, such as Candida auris – responsible for increasing rates of invasive fungal infections in hospitals across the globe. It was found to be resistant to all antifungal drugs and "presents a threat to intensive-care units" as it can survive standard decontamination efforts.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial